An ISO9001 Certified Supplier of Pharmaceutical Ingredients and Specialty Chemicals

MYRBETRIQ®

Drug Information Related Patent
Hold Company
Astellas Pharma US, Inc
Learn More
Dosage and Administration
TABLET, EXTENDED RELEASE;ORAL
Specification
25MG; 50MG
Indication
MYRBETRIQ® is indicated for adults with overactive bladder (OAB) and children with neurogenic detrusor overactivity (NDO).
Use
Instructions for Use
API
MIRABEGRON
API Structure
We Supply
MIRABEGRON
Note:

USP/In-house Standard/CP
Facility GMP
USMF/DMF/WC/ASMF/KDMF

null
Note:

null

null
Note:

null

Drug Patent
Patent NoExpiration Date
108427802029/9/28
10842780*PED2030/3/28
117074512029/9/28
11707451*PED2030/3/28
73421172023/11/4
7342117*PED2024/5/4
79820492023/11/4
7982049*PED2024/5/4
87723152028/10/30
8772315*PED2029/4/30
88354742023/11/4
8835474*PED2024/5/4
RE448722023/11/4
RE44872*PED2024/5/4
API Patent
Patent NoExpiration Date
73421172023/11/4
7342117*PED2024/5/4
79820492023/11/4
7982049*PED2024/5/4

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION
CONTACT US
  • Tel:
  • E-mail:
  • Address:
  • WhatsAPP
    WhatsAPP
Privacy Policy | Cookie Policy
Copyright © Protheragen. All Rights Reserved.
Member of
dcat
CERTIFICATION
dcat
dcat dcat dcat dcat
Top